Editas Medicine
EDIT
256 hedge funds and large institutions have $561M invested in Editas Medicine in 2022 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 71 increasing their positions, 74 reducing their positions, and 35 closing their positions.
2.94% more ownership
Funds ownership: 66.23% → 69.17% (+2.9%)
9% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 35
0% more funds holding
Funds holding: 256 → 256 (0)
4% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 74
5% less call options, than puts
Call options by funds: $19.9M | Put options by funds: $20.8M
35% less capital invested
Capital invested by funds: $862M → $561M (-$301M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$32.2M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$13.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$9.02M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$8.44M |
| 5 |
BlackRock
New York
|
+$6.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$17.2M |
| 2 |
Millennium Management
New York
|
-$7.99M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$7.29M |
| 4 |
CU
CQS (US)
New York
|
-$6.41M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$4.44M |
EDIT Hedge Fund Activity: Q2 2022 in Review
256 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q2 2022, worth a combined $561M — down 35% from $862M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new EDIT positions and 35 closed out — a net gain of 3 holders — while 71 added to existing stakes and 74 trimmed.
The largest buyer was State Street, adding an estimated $32.2M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $17.2M sold.
- 256 institutional investors held Editas Medicine (EDIT) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $561M of Editas Medicine stock for Q2 2022, down 35% quarter-over-quarter.
- 38 funds opened new Editas Medicine positions in Q2 2022 and 35 closed out, a net change of +3 holders.
- The largest Editas Medicine buyer in Q2 2022 was State Street, an estimated $32.2M added.
- The largest Editas Medicine seller in Q2 2022 was Renaissance Technologies, an estimated $17.2M sold.
Based on aggregated 13F filings for Q2 2022.